Meneghini L, Blonde L, Gill J, et al. - Researchers tested the safety and efficacy of insulin glargine 300 U/mL (Gla‐300) vs standard‐of‐care basal insulin analogues (SOC‐BI) at 12 months in the ACHIEVE Control trial, which is a prospective pragmatic randomized real‐life study in insulin‐naïve adults with type 2 diabetes (T2D). In total, 3,304 insulin‐naïve adults with T2D and glycated haemoglobin concentration of 64 to 97 mmol/mol after ≥1 year of treatment with two or more antihyperglycaemic agents were randomized to Gla‐300 or SOC‐BI. In real‐world clinical practice, Gla‐300 appeared to be linked to a lower risk of hypoglycaemia than SOC‐BI during the 12‐month follow‐up.